• Bionano Genomics, Inc. will present at the H.C.
• Wainwright 26th Annual Global Investment Conference on September 9th, 2024.
• Erik Holmlin, PhD, Bionano’s president and CEO, will present at the conference.
• The presentation will take place from 11:00 a.m. to 11:30 a.m.
• The event will be available through the Bionano website for at least.
SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9th, 2024.
Conference & Webcast Details
| Date: | September 9, 2024 |
| Time: | 11:00 a.m. to 11:30 a.m. ET |
| Presenter: | Erik Holmlin, PhD, CEO of Bionano |
| Webcast: | Link to Register |
A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 30 days.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For more information, visit bionano.com and bionanolaboratories.com.
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.42 |
| Daily Change: | -0.01 -2.95 |
| Daily Volume: | 1,179,285 |
| Market Cap: | US$35.900M |
August 07, 2024 July 23, 2024 July 08, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
